Follicular lymphoma: Are we ready for a risk-adapted approach?

Keyphrases

• Follicular Lymphoma 100%
• Risk-based Approach 100%
• High Risk 66%
• Clinical High Risk 66%
• Rituximab 66%
• International Prognostic Index 66%
• Remission 33%
• PET Imaging 33%
• Working Diagnosis 33%
• Initial Treatment 33%
• Overall Survival 33%
• CARD11 33%
• EP300 33%
• CREB1 33%
• Low Risk 33%
• Tumor Grade 33%
• Mutational Status 33%
• Poor Outcome 33%
• First-line Therapy 33%
• Risk Stratification 33%
• Conventional Chemotherapy 33%
• Enhancer of Zeste Homolog 2 (EZH2) 33%
• Targeted Agents 33%
• Tumor Burden 33%
• Randomized Clinical Trial 33%
• Natural History 33%
• Indolent non-Hodgkin Lymphoma 33%
• Western Hemisphere 33%
• Predictive Biomarker 33%
• Targeting Strategies 33%
• Unmet Needs 33%
• Biological Factors 33%
• ARID1A 33%
• MEF2B 33%
• FOX01 33%

Medicine and Dentistry

• Neoplasm 100%
• Follicular Lymphoma 100%
• Rituximab 100%
• Follicular Lymphoma International Prognostic Index 100%
• Biological Marker 50%
• Positron Emission Tomography 50%
• Overall Survival 50%
• Non-Hodgkin Lymphoma 50%
• Induction Chemotherapy 50%
• Hemisphere 50%
• Diseases 50%
• Randomized Clinical Trials 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Follicular Lymphoma 100%
• Neoplasm 66%
• Rituximab 66%
• Biological Marker 33%
• Overall Survival 33%
• Chemotherapy 33%
• Remission 33%
• Nonhodgkin Lymphoma 33%
• Randomized Clinical Trial 33%
• Polyethylene Terephthalate 33%
• Diseases 33%